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usage. To start with, high-grade brain tumors are charac-
terized by low activity of adenylyl cyclase and/or deple-
tion of cytoplasmic cAMP. Concomitantly, glioma and 
astrocytoma cell lines like A-172 and 1321N1 are highly 
susceptible to increased production of cAMP, which can 
be achieved by treatment with cAMP analogues, adenylyl 
cyclase activators or phosphodiesterase inhibitors (Chen 
et al. 1998; Toll et al. 2011). It is not surprising that ago-
nists of β-AR can mimic the antiproliferative effects of the 
above-mentioned compounds, as canonical β-AR signaling 
pathway involves the  Gs-dependent activation of adenylyl 
cyclase and subsequent accumulation of cAMP (Toll et al. 
2011). In our study carried out in 1321N1 cells, the level 
of cAMP induced by the β2-AR agonists like fenoterol and 
isoproterenol positively correlated with decreased mitogen-
esis (Fig. 1). Similarly, decreased cell growth was observed 
in response to β-AR agonists in nontumor breast MCF-10A 
cells (Bruzzone et  al. 2014) and in breast cancer cell line 
MDA-MB-231 (Carie and Sebti 2007). In significance, 
Gargiulo et  al. demonstrated that β2-AR knock-down led 
to increase of cell proliferation and migration of MCF-7 
breast cancer cell line, indicating that β2-AR exerts an 
inhibitory tone towards cell growth and motility at basal 
conditions (Gargiulo et al. 2014). When the same cell line 
was engineered to overexpress β2-AR, significant drop in 
cell growth and migration was observed (Gargiulo et  al. 
2014). In line with this work, our unpublished data on rat 
C6 glioma cells indicate that siRNA-mediated depletion of 
β2-AR leads to significant increase in phosphoactive forms 
of AKT and ERK1/2. Taken together, expression level of 
the β2-AR receptor is an important factor shaping the pro-
liferative capacity of cancer cells, and should be taken into 
account when studying the cellular responses to β2-AR 
ligands.
To Editor,
In a recent issue of Journal of Cancer Research and Clini-
cal Oncology, Coelho et  al. (2017) reviewed preclinical 
and epidemiological reports regarding changes in cellular 
proliferation in response to β-adrenergic receptor (β-AR) 
ligands. The authors indicated that cancer cells commonly 
express both β1 and β2 adrenoceptors and that the agonist-
mediated activation of these receptors leads to increased 
proliferation of cultured cells of different origin. Conse-
quently, β-blockers (β-AR antagonists) were proposed as 
adjuvants for cancer management. This was supported by 
numerous pharmacoepidemiological studies indicating 
that cancer patients experience beneficial effects like pro-
longed survival or reduced risk of metastasis due to chronic 
β-blocker intake for cancer-unrelated heart conditions (Bar-
ron et al. 2011; Lemeshow et al. 2011).
As noted by the authors, the amount of data generated 
over time strongly supports the notion that blockage of 
β-ARs may constitute a novel therapeutic option for cancer. 
However, a non-negligible body of evidence indicates that 
opposite measures—i.e. activation of β-AR—may also be 
effective in suppressing the growth of cancer cells, at least 
in some cases (Strell et al. 2012). Thus, the purpose of this 
letter is to highlight the studies demonstrating antitumori-
genic effects of β-AR activation, as opposed to β-blocker 
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Results from developmental studies also contribute to 
the knowledge on β-AR function in highly proliferative 
cells. Activation of β-ARs in murine embryonic pluripotent 
stem cells inhibits proliferation and cell cycle progression 
via cAMP and PKA (Sun et  al. 2015). This is consistent 
with the finding that propranolol treatment in Xenopus lae-
vis embryos encourages a neoplastic-like phenotype char-
acterized by hyperpigmentation and increased melanocyte 
count (Sullivan and Levin 2016). We made compatible 
observations in human-derived UACC-647, M93-047 and 
UACC-903 melanoma cells: treatment with β2-AR ago-
nists (isoproterenol, fenoterol) markedly delayed prolifera-
tion and invasiveness of the melanoma cells (Wnorowski 
et  al. 2015). These functional responses were accom-
panied by drop in ERK1/2 phosphorylation. Pharmaco-
logical approach enabled us to map the signaling pathway 
responsible for the observed effects to β2-AR/Gs/adenylyl 
cyclase/cAMP/PKA (Wnorowski et al. 2015). Comparable 
observations were made by Bruzzone and colleagues, who 
identified that isoproterenol mediates its antiproliferative 
actions by the activation of β2-AR/cAMP/PKA and boosts 
cell adhesion by triggering β2-AR/cAMP/EPAC in human 
breast cells (Bruzzone et al. 2014).
Plethora of epidemiological studies indicated that can-
cer patients benefit from β-blockers usage. For instance, 
population-based cohort study from Denmark showed that 
β-blocker treatment reduces risk of death in malignant 
melanoma patients (Lemeshow et  al. 2011). Similarly, 
Watkins et  al. reported longer median overall survival in 
ovarian cancer patients receiving nonselective β-blockers 
compared to nonusers (2015). However, some other reports 
failed to confirm the association between β-blocker use 
and decreased mortality following ovarian cancer diagno-
sis (Eskander et al. 2012; Johannesdottir et al. 2013). It has 
been speculated that some of the epidemiological reports 
on β-blockers can suffer from the immortal person-time 
bias (Schmidt and Schmidt 2016). This type of statistical 
bias arises when exposure to β-blocker occurs after the start 
of follow-up (i.e. after the cancer diagnosis). In such case, 
the time that patients have to survive between the start of 
follow-up to the initiation of β-blocker intake is referred to 
as “immortal”, as the patient needs to survive it to be clas-
sified as exposed to the drug. Inclusion of this immortal 
time leads to overestimation of the overall survival time in 
exposed group compared to nonusers (Suissa 2008). Thus, 
skew by an immortal time bias can constitute a probable 
explanation to discrepancies in retrospective pharmacoepi-
demiological studies on β-blocker effectiveness in ovarian 
cancer, and possibly in other cancer types (Weberpals et al. 
2016).
Conclusions
β-Blockers are commonly used drugs with well-defined 
pharmacokinetic and pharmacodynamic profiles and gener-
ally mild side effects (Hilal-Dandan et al. 2017). It would 
be greatly appreciated if these relatively inexpensive drugs 
were proven effective as supportive agents in standard 
chemotherapy or as standalone cancer prevention agents. 
Hopefully, ongoing clinical trials will confirm the feasibil-
ity of β-blockers usage in cancer management. However, 
in some types of cancer cells an opposite approach may be 
more suitable. Preclinical studies indicate that in some sys-
tems agonist-mediated activation of β-ARs efficiently sup-
presses cellular proliferation and, thus, is more beneficial 
than the treatment with β-blockers. We believe that there 
is an urgent need to understand why some cancer cells are 
susceptible to β-AR antagonists, while others are attenu-
ated by agonists of β-ARs.
We fully agree with Coelho et  al. that further studies 
are necessary to decipher the complexity of intracellular 
signaling triggered by different classes of β-AR ligands. 
When studying effects of such compounds, one should 
take into account the qualitative and quantitative vari-
ability in the composition of cellular signaling machinery, 
including the expression level and localization of adreno-
ceptors (Gargiulo et  al. 2014) and downstream signaling 
proteins (Skalhegg and Tasken 2000) in the cells of inter-
est. Availability of non-adrenergic receptors to oligomer-
ize with β-ARs should be also acknowledged (Wnorowski 
and Jozwiak 2014). Moreover, single-dose experiments 
should be avoided in favor of dose-ranging studies, as 
Fig. 1  Antiproliferative effects of β2-AR agonists in 1321N1 astrocy-
toma cells. Selected β2-AR agonists were tested for the cAMP accu-
mulation and for the  [3H]thymidine incorporation in 1321N1 cells. 
Linear regression demonstrated that compounds more potent accord-
ing to the capacity to induce cAMP production were also better inhib-
itors of thymidine incorporation. ISO isoproterenol, Fen fenoterol, 
MFen 4′-methoxyfenoterol, MNF 4′-methoxy-1-naphthylfenoterol. 
The graph was generated by plotting the data retrieved from the work 
of Toll et al. (2011)
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cellular responses to β-AR ligands tend to follow bipha-
sic, bell-shaped or U-shaped curves (Bruzzone et al. 2014; 
Wnorowski et al. 2015). With new data being consistently 
generated, we may ultimately be able to predict the cellular 
responses of a given cell type to agonists and antagonists of 
β-ARs and exploit this knowledge to produce desired cellu-
lar effect, hopefully in clinically relevant manner.
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